e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis
Christina Morse, Tracy Tabib, John Sembrat, Kristina L. Buschur, Humberto Trejo Bittar, Eleanor Valenzi, Yale Jiang, Daniel J. Kass, Kevin Gibson, Wei Chen, Ana Mora, Panayiotis V. Benos, Mauricio Rojas, Robert Lafyatis
Source:
Eur Respir J, 54 (2) 1802441; 10.1183/13993003.02441-2018
Journal Issue:
August
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Christina Morse, Tracy Tabib, John Sembrat, Kristina L. Buschur, Humberto Trejo Bittar, Eleanor Valenzi, Yale Jiang, Daniel J. Kass, Kevin Gibson, Wei Chen, Ana Mora, Panayiotis V. Benos, Mauricio Rojas, Robert Lafyatis. Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis. Eur Respir J, 54 (2) 1802441; 10.1183/13993003.02441-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Apoptosis in epithelial cells in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2004; 24: Suppl. 48, 481s
Year: 2004
Tryptase+ mast cells associate with fibrotic regions in the lungs of idiopathic pulmonary fibrosis patients; a multiplex staining approach
Source: International Congress 2016 – How the understanding og molecular and genomic crosstalk is helping to diagnose lung disease
Year: 2016
Epithelium involvement and remodeling of interstitium in idiopathic pulmonary fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 745s
Year: 2006
Role of dendritic cells in pulmonary fibrosis in mice
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Role of MUC1 in idiopathic pulmonary fibrosis
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Decreased BCL-2 expression in alveolar macrophages of patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
Distinctive polarization of circulating classical monocytes between idiopathic pulmonary fibrosis and idiopathic nonspecific interstitial pneumonia.
Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Year: 2020
VEGF expression does not differentiate between idiopathic pulmonary fibrosis and pulmonary sarcoidosis
Source: Eur Respir J 2007; 30: Suppl. 51, 574s
Year: 2007
Fibrocytes are a potential source of fibroblasts in idiopathic pulmonary fibrosis
Source: Eur Respir J 2007; 30: Suppl. 51, 719s
Year: 2007
Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Airway remodelling: recent developments
Year: 2015
Clinical and functional features in idiopathic pulmonary fibrosis (IPF) with and without haemosiderin-laden alveolar macrophages on BALF
Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Year: 2011
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Role of midkine in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Aquoaporin-1 expression in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Expression of apoptotic markers in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 376s
Year: 2003
Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Circulating monocytes from interstitial lung disease patients show an activated phenotype
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Abnormal proliferation and differentiation of c-kit+ lung stem cells in pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis?
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept